UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,096	04/10/2006	Harue Nishiya	Q105188	9627
65565 SUGHRUE-265	7590 04/01/200 5 <b>550</b>	9	EXAMINER	
2100 PENNSY	LVANIA AVE. NW		ZARA, JANE J	
WASHINGTON, DC 20037-3213			ART UNIT	PAPER NUMBER
			1635	
			MAIL DATE	DELIVERY MODE
			04/01/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/575,096	NISHIYA ET AL.		
Office Action Summary	Examiner	Art Unit		
	Jane Zara	1635		
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION (36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
<ol> <li>Responsive to communication(s) filed on 10 A</li> <li>This action is FINAL.</li> <li>Since this application is in condition for alloward closed in accordance with the practice under B</li> </ol>	s action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) ☐ Claim(s) 1-28 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-28 are subject to restriction and/or	wn from consideration.			
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct to by the Examine and the second and the second area of the second and the second area of the second area.	epted or b) objected to by the I drawing(s) be held in abeyance. See tion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal F 6) Other:	ate		

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-16 drawn to a processes for producing an antibody composition.

Group II, claim(s) 17-19, drawn to cells comprising RNA capable of suppressing function of an enzyme.

Group III, claim(s) 20-24, drawn to nucleic acids and transformants.

Group IV, claim(s) 25-26, drawn to method for constructing lectin-resistant cells

Group V, claim(s) 27-28, drawn to methods of suppressing the function of an enzyme

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Claims 1-28 are drawn to a methods, processes, cells and compositions comprising or utilizing a plurality of double-stranded RNA molecules (SEQ ID NOs. 9 to 30), nucleic acids encoding different fucosyltransferases (SEQ ID NOs. 1-8), lectins, and cell types. Therefore, this application does not comply with the requirements for unity of invention (Rules 13.1, 13.2 and 13.3) for the following reasons:

According to the guidelines in section (f)(i)(a) of annex B of the PCT

Administrative Instruction, the special technical feature as defined by PCT Rule 13.2

shall be considered to be met when all the alternatives of a Markush group are of similar

Art Unit: 1635

nature. The instant methods, cells and compositions comprising or utilizing a plurality of double-stranded RNA molecules (SEQ ID NOs. 9 to 30), nucleic acids encoding different fucosyltransferases (SEQ ID NOs. 1-8), lectins, and cell types, etc. set forth in and/or encompassed by claims 1-28 are considered to be each separate inventions for the following reasons:

The different sequences, nucleic acids, targets, structures, processes, methods and cell types do not meet the criteria of (A), common property or activity or (B)(2), art recognized class of compounds. In the instant case, the different target molecules, target genes, double stranded RNA molecules and other nucleic acids, proteins, lectins, cell types are structurally and chemically and biologically different and distinct, and the different molecules and biological structures and entities, and the different methods and screening processes target different molecules, inhibit protein activity, or modulate the expression of the target gene to varying degrees, or measure different phenotypes, biochemical and/or biological effects. Each member of the class cannot be substituted one for the other with the expectation that the same intended result would be achieved or measured.

Further, the different Groups of compounds and target molecules and processing constructs, and the different methods do not meet the criteria of (B)(1) as they do not share, one with another, a common core structure. Accordingly, unity of invention between the double-stranded RNA molecules (SEQ ID NOs. 9 to 30), nucleic acids encoding different fucosyltransferases (SEQ ID NOs. 1-8), lectins, and cell types

is lacking and each target molecule is considered to constitute a special technical feature.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

## Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. ' 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original

Application/Control Number: 10/575,096 Page 5

Art Unit: 1635

signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jane Zara whose telephone number is (571) 272-0765. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Douglas Schultz, can be reached on (571) 272-0763. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jane Zara 3-27-09

/Jane Zara/ Primary Examiner, Art Unit 1635